0HUZ Stock Chart & Stats
$11.48
$0.00(0.00%)
At close: 4:00 PM EDT
$11.48
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.48 - $11.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$4.67M
Enterprise Value$10.29M
Total Cash (Recent Filing)$6.86M
Total Debt (Recent Filing)$7.85M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Nov 16, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend Yield11.75%
Share Statistics
EPS (TTM)-4.53
Shares Outstanding5,611,403
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-61.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$15.67Price Target Upside36.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe reported overall-survival gains provide meaningful clinical validation for IMUNON-001 and could support differentiation in ovarian cancer if confirmed. Durable efficacy evidence may improve the program’s partnering, regulatory, and adoption potential as later-stage data mature.
Phase III ExecutionEnrollment materially ahead of plan indicates that the pivotal program is attracting patients and that site activation is functioning effectively. Sustained execution can shorten operational bottlenecks, improve trial predictability, and accelerate the path toward confirmatory clinical evidence.
Strategic FocusDivesting a legacy asset can simplify the portfolio and concentrate management attention and capital on IMNN-001, the company’s principal value-creating program. Potential milestones, royalties, and an equity stake also preserve upside if the buyer successfully advances ThermoDox.
Bears Say
No Meaningful RevenueThe absence of a meaningful revenue base leaves the company dependent on clinical progress and external financing rather than internally generated commercial cash flow. Persistent losses also reduce earnings visibility and make the business more vulnerable if development milestones are delayed.
Cash Burn And Funding DependenceContinued operating cash consumption, together with a sharply higher TTM outflow, creates sustained financing pressure while Phase III spending increases. The stated runway only extends through year-end 2026, so future execution depends on raising additional capital on acceptable terms.
Clinical Statistical UncertaintyEncouraging MRD signals may not translate into reliable evidence because the study’s small, exploratory design limits statistical certainty. Until larger confirmatory datasets are available, this uncertainty can constrain confidence in biomarker performance, regulatory value, and eventual clinical adoption.
Imunon News
0HUZ FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest share price was $11.48 and its highest was $11.48 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $4.67M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Nov 16, 2026 which is in 16 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Aug 11, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.868 by $0.328.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon pays a Notavailable dividend of $0.182 which represents an annual dividend yield of 11.75%. See more information on Imunon dividends here
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.55.
How many shares outstanding does Imunon have?
Imunon has 5,611,403 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.868. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in GB:0HUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
0HUZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and translational momentum (robust Phase II OS gains, encouraging MRD signals, favorable safety) and operational execution (enrollment outperforming assumptions, cost discipline, recent financing), balanced against near-term financing needs and uncertainties tied to small MRD sample size and event-driven timing of Phase III interims. Overall the positives (clinical validation, enrollment traction, operational control) outweigh the negatives (short runway, need for additional capital, statistical limitations of MRD).View all GB:0HUZ earnings summaries0HUZ Stock 12 Month Forecast
Average Price Target
$15.67
▲(36.47% Upside)